Targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma

Osteosarcoma Webinar Series: Ali Cihan, PhD, a research scholar at Memorial Sloan Kettering Cancer Center, will discuss his OutSmarting Osteosarcoma funded work on targeting EPHA2 with dual-armored CAR T cells for immunotherapy in pediatric osteosarcoma.Dr. Ali Cihan is a research scholar at Memorial Sloan Kettering Cancer Center, where he focuses on immunotherapy with a particular emphasis on advancing cellular therapies for pediatric solid tumors, including osteosarcoma. He received his Ph.D. from The Rockefeller University, where his research explored how chromosomal abnormalities and transcriptional dysregulation contribute to the development of high-risk pediatric leukemias. Motivated by the urgent need to improve outcomes for children with cancer, especially those facing limited treatment options, Dr. Cihan turned his focus to bridging laboratory discoveries and clinical application. His current work aims to develop immune-based therapeutic strategies that address the unique biological and clinical challenges of pediatric cancers.